Figure 6.
Indole-3-carbinol and bortezomib co-treatment inhibit human ovarian tumour xenografts in nude mice. (A) Relative tumour growth of OVCAR5 xenografts treated with vehicle (control), 20 mg kg−1 I3C, 1 mg kg−1 bortezomib or in combination measured from 0 to 53 days post treatment or (B) measured 42, 45, 49 and 53 days post treatment. The data shown represent the mean±s.e.m. (n=8). (C) Representative tumour images of control- (vehicle), I3C- and bortezomib-treated mice pre and post dissection, with corresponding (D) tumour weight 53 days post treatment. The data shown represent the mean±s.e.m. (n=8).